Trials / Completed
CompletedNCT00634985
Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs
A Multicentre, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Eletriptan 40 Mg for the Treatment of Migraine (With or Without Aura) in Subjects Unsuccessfully Treated With NSAIDS
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
To assess the safety and efficacy of eletriptan for the treatment of migraine in subjects who had not been adequately treated with non-steroidal antiinflammatory drugs (NSAIDs)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | eletriptan | 40 mg oral tablet for migraine attack; additional 40 mg oral tablet \>2 hours from first dose if migraine reoccurred within 24 hours of achieving response |
Timeline
- Start date
- 2002-11-01
- Completion
- 2003-12-01
- First posted
- 2008-03-13
- Last updated
- 2021-01-27
Locations
6 sites across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00634985. Inclusion in this directory is not an endorsement.